We got to meet the amazing Dr. Glaucomflecken! #ASCOAdvocacy ASCO TECAG @ASCO Fernando Diaz, MD

This crew of fearless early career #WomenInOncology is ready to take on #CapitolHill tomorrow & advocate for #CancerResearch funding, ending drug shortages, & more!
Thanks ASCO for bringing us together!

📸 by the amazing Fumiko Ladd Chino, MD ❤️🙏🏽
#ASCOAdvocacy
#ASCOAdvocacy Summitt…

T-DXd is approved for the treatment of patients with ANY treatment-refractory HER2+ (IHC 3+) tumor, making of it the first agnostic ADC. Unlikely to be the last. Key priority: ensuring that HER2 testing is expanded across cancer types. Exciting times! fda.gov/drugs/resource…

Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases | New England Journal of Medicine nejm.org/doi/full/10.10… Continued de-escalation of local therapies in breast cancer.

EHR giant Epic plans to release an AI validation software suite to enable healthcare organizations to evaluate AI models at the local level and monitor those systems over time.

fiercehealthcare.com/ai-and-machine…
#EHR #Epic #artificialintelligence #NLP

astrazeneca.com/media-centre/p…

The OXEL trial, led by Filipa Lynce, MD, FASCO, is out on Nature Communications. Among 45 pts with residual TNBC after NAT, adjuvant nivo/cape were well tolerated, increased peripheral immune score & led to numerically improved 2y iDFS (91%) vs nivo (47%) or cape alone (53%). nature.com/articles/s4146…

PARP Inhibitors for Breast Cancer Treatment jamanetwork.com/journals/jamao…

Out in JCO, the PACE randomized phase 2 trial by Erica Mayer Sara Tolaney et al. Among pts with HR+ MBC and prior progression on CDK4/6i (90% palbo), adding palbo to fulvestrant did not improve PFS (4.6 vs 4.8 mo). Interesting signal with fulv/palbo/avelumab. ascopubs.org/doi/10.1200/JC…

Grand Rounds this week with Ilana Schlam from our Division of Heme-Onc
Andreas Klein, MD Tufts Medical Center Sucharita Kher MD

Just issued: Rapid guideline update on endocrine and targeted therapy for HR-positive, HER2-negative metastatic #BreastCancer - capivasertib-fulvestrant. Read more: brnw.ch/21wHQVC #bcsm #mBC

Don’t miss this virtual info session! All interested attendees are welcome. Program highlights:
·         Single NRMP match
·         Consolidated training
·         Integrated curriculum
ASCO ASCOTECAG ASCO OncMedEdCoP

Addressing Residual Disease in #HER2 + and #TripleNegativeBreastCancer : What Is Next?
New #TNBC review in Current Oncology Reports from
Ilana Schlam #JoshuaDower Filipa Lynce, MD, FASCO
👉pubmed.ncbi.nlm.nih.gov/38393609/

Hot off the press The Breast Online - our summary of highlights in metastatic breast cancer in 2023: recent practice changing publications, approvals and some unanswered clinical questions

thebreastonline.com/article/S0960-…

Very useful tables for easy reference.
ADC in MBC .
CDK inhibitors in MBC in first line .
Cdk inhibitors after cdk inhibitors in MBC .
PIK3CA/ Mtor / AKT inhibitors in MBC . Taken From article in The Breast Online
By Ilana Schlam and by Dr Mariana Chavez -Macgregor 👍👍

💥The autologous tumor infiltrating lymphocyte (TIL) cell therapy lifileucel (Amtagvi) received U.S. FDA accelerated approval today for pretreated unresectable/metastatic melanoma. Approval is based on the results of the ph2 C-144-01 trial (NCT02360579)

fda.gov/news-events/pr…

KEYNOTE-522 outcomes by RCB out on Annals of Oncology. Largest benefit from pembro was observed in the RCB-2 group. Striking difference in 3-year EFS between RCB-1 (≃84%) and RCB-3 (≃30%): not all residual disease is created equal! annalsofoncology.org/article/S0923-…

#TumorBoardTuesday
👉Antibody-Drug conjugates are everywhere now, and understanding how best to use them is becoming challenging

📢Join us Tuesday, 02-06-24 at 8PM ET as Yara Abdou, MD & Joannie M. Ivory, MD, MSPH, MHS🗣️sequencing of ADCs in #breastcancer Tx

🔔RT and bring others into the discussion‼️

Check out our new review led by our stellar fellow Fei Song - Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better?

Sara Tolaney Paolo Tarantino Filipa Lynce, MD, FASCO Tufts Medical Center

link.springer.com/epdf/10.1007/s…

Great work by Chiara Corti - review exploring the hurdles associated with the development, implementation, and maintenance of #AI in patient care

Sara Tolaney OncoAlert